1-(3,5-Dicyclopropylpyridin-2-yl)piperazine → HCID 86676773, 화합물
반응식
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[C:4]([CH3:11])[N:3]=1.[CH:12]1([C:15]2[C:16]([N:24]3[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]3)=[N:17][CH:18]=[C:19]([CH:21]3[CH2:23][CH2:22]3)[CH:20]=2)[CH2:14][CH2:13]1>>[Br:1][C:2]1[N:3]=[C:4]([CH3:11])[C:5]([C:6]([N:27]2[CH2:28][CH2:29][N:24]([C:16]3[C:15]([CH:12]4[CH2:13][CH2:14]4)=[CH:20][C:19]([CH:21]4[CH2:23][CH2:22]4)=[CH:18][N:17]=3)[CH2:25][CH2:26]2)=[O:8])=[CH:9][CH:10]=1참가 물질
3
실험 절차
Using 6-bromo-2-methylnicotinic acid (604 mg) and 1-(3,5-dicyclopropylpyridin-2-yl)piperazine (816 mg) described in Preparation Example 88 and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (695 mg) was obtained.
후처리
- customdescribed in Preparation Example 88 and by the reaction and treatment in the same manner as in Preparation Example 111
출처 및 근거
- ORD 기록
- ord-6585959be48d431faace28190830358e